Terms: = Leukemia AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
16 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Identification of cellular senescence-related signature for predicting prognosis and therapeutic response of acute myeloid leukemia.
Zhong F; Yang Y; Yao F; Liu J; Yu X; Wang XL; Huang B; Wang XZ
Aging (Albany NY); 2023 Oct; 15(20):11217-11226. PubMed ID: 37845004
[TBL] [Abstract] [Full Text] [Related]
3. Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome.
Štach M; Pytlík R; Šmilauerová K; Rychlá J; Mucha M; Musil J; Koladiya A; Nemec M; Petráčková M; Kaštánková I; Pecherková P; Šrámková L; Polgárová K; Trněný M; Lesný P; Vydra J; Otáhal P
Pathol Oncol Res; 2023; 29():1610914. PubMed ID: 37151356
[TBL] [Abstract] [Full Text] [Related]
4. Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia.
Huang Y; Zheng H; Zhu Y; Hong Y; Zha J; Lin Z; Li Z; Wang C; Fang Z; Yu X; Liu L; Xu B
Front Immunol; 2023; 14():1139517. PubMed ID: 36960073
[TBL] [Abstract] [Full Text] [Related]
5. Somatic mutation-associated risk index based on lncRNA expression for predicting prognosis in acute myeloid leukemia.
Xu Q; Guo T
Hematology; 2022 Dec; 27(1):659-671. PubMed ID: 35666642
[No Abstract] [Full Text] [Related]
6. Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome.
Di Raimondo C; Rubio-Gonzalez B; Palmer J; Weisenburger DD; Zain J; Wu X; Han Z; Rosen ST; Song JY; Querfeld C
Br J Dermatol; 2022 Aug; 187(2):234-243. PubMed ID: 35194801
[TBL] [Abstract] [Full Text] [Related]
7. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Sams L; Kruger S; Heinemann V; Bararia D; Haebe S; Alig S; Haas M; Zhang D; Westphalen CB; Ormanns S; Metzger P; Werner J; Weigert O; von Bergwelt-Baildon M; Rataj F; Kobold S; Boeck S
Clin Transl Oncol; 2021 Nov; 23(11):2394-2401. PubMed ID: 33876417
[TBL] [Abstract] [Full Text] [Related]
8. TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients.
Rakova J; Truxova I; Holicek P; Salek C; Hensler M; Kasikova L; Pasulka J; Holubova M; Kovar M; Lysak D; Kline JP; Racil Z; Galluzzi L; Spisek R; Fucikova J
Oncoimmunology; 2021 Mar; 10(1):1889822. PubMed ID: 33758676
[TBL] [Abstract] [Full Text] [Related]
9. Programmed cell death 1-expressing CD56-negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment.
Ishiyama KI; Kitawaki T; Otsuka Y; Takaori-Kondo A; Kadowaki N
Cancer Sci; 2021 Feb; 112(2):523-536. PubMed ID: 33064914
[TBL] [Abstract] [Full Text] [Related]
10. Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence.
Huemer F; Leisch M; Geisberger R; Melchardt T; Rinnerthaler G; Zaborsky N; Greil R
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325898
[TBL] [Abstract] [Full Text] [Related]
11. A skewed distribution and increased pd-1+Vβ+CD4+/CD8+ T cells in patients with acute myeloid leukemia.
Huang J; Tan J; Chen Y; Huang S; Xu L; Zhang Y; Lu Y; Yu Z; Chen S; Li Y
J Leukoc Biol; 2019 Sep; 106(3):725-732. PubMed ID: 31136687
[TBL] [Abstract] [Full Text] [Related]
12. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of pd-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract] [Full Text] [Related]
13. Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.
Kawamoto K; Miyoshi H; Suzuki T; Kiyasu J; Yokoyama S; Sasaki Y; Sone H; Seto M; Takizawa J; Ohshima K
Hematol Oncol; 2018 Aug; 36(3):591-599. PubMed ID: 29602174
[TBL] [Abstract] [Full Text] [Related]
14. Markers and function of human NK cells in normal and pathological conditions.
Del Zotto G; Marcenaro E; Vacca P; Sivori S; Pende D; Della Chiesa M; Moretta F; Ingegnere T; Mingari MC; Moretta A; Moretta L
Cytometry B Clin Cytom; 2017 Mar; 92(2):100-114. PubMed ID: 28054442
[TBL] [Abstract] [Full Text] [Related]
15. Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.
Lipowska-Bhalla G; Fagnano E; Illidge TM; Cheadle EJ
Leuk Lymphoma; 2016; 57(6):1269-80. PubMed ID: 27050042
[TBL] [Abstract] [Full Text] [Related]
16. Expansion of a CD8(+)pd-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.
Nunes C; Wong R; Mason M; Fegan C; Man S; Pepper C
Clin Cancer Res; 2012 Feb; 18(3):678-87. PubMed ID: 22190592
[TBL] [Abstract] [Full Text] [Related]